NCT05145361View on ClinicalTrials.gov

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

December 15, 2025

Study Completion Date

December 15, 2025

Conditions
NMO Spectrum Disorder
Interventions
DRUG

B001 injection

B001 injection 50mg/5mL Intravenous solution

BIOLOGICAL

Placebo

Placebo 5mL Intravenous solution

Trial Locations (4)

100050

RECRUITING

Beijing Tiantan Hospital Capital Medical University, Beijing

300052

RECRUITING

Tianjin Medical University General Hospital, Tianjin

710038

RECRUITING

Tangdu hospital,fourth military medical university, Xi’an

030001

RECRUITING

First Hospital of Shanxi Medical University, Taiyuan

All Listed Sponsors
lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY